Bunazosin
Alternative Names: Andante; Detantol; E 1015; E 643; EA 0643Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Eisai Co Ltd
- Developer Boehringer Ingelheim; Eisai Co Ltd; Santen Pharmaceutical
- Class Antihypertensives; Eye disorder therapies; Quinazolines; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Glaucoma; Heart failure; Hypertension; Ocular hypertension
Most Recent Events
- 07 Nov 2001 Launched for Glaucoma in Japan (Ophthalmic)
- 07 Nov 2001 Launched for Ocular hypertension in Japan (Ophthalmic)
- 19 Jun 2001 Registered for Glaucoma in Japan (Ophthalmic)